Substituted Pyrazoles as Modulators of Chemokine Receptors

A compound represented by Formula (I):

• wherein:
• R1 and R2 are each independently selected from —(C0-6alkyl)-W—(C6-14aryl), —(C0-6alkyl)-W-heterocycle and —(C0-6alkyl)-W—(C3-7cycloalkyl);
• R3 and R4 are each independently selected from —C0-6alkyl, —(C0-6alkyl)-W—(C1-6alkyl), —(C0-6alkyl)-W—(C3-7cycloalkyl), —(C0-6alkyl)-W—(C6-14aryl), —(C0-6alkyl)-W-heterocycle, and —C(O)OR6;
• where each of R1, R2, R3 and R4 is independently unsubstituted or substituted with 1-7 substituents, where each of said 1-7 substituents is independently selected from halo, hydroxy, —O—C1-3alkyl, trifluoromethyl, —C1-3alkyl, —CO2R6, —CN, —N(R6)2, —NR6COR6, —NRSO2R6, and —CONR6;
• R5 is selected from hydrogen, —C0-6alkyl, —(C0-6alkyl)—(C6-14aryl), —(C0-6alkyl)-heterocycle, —(C0-6alkyl)-C3-7cycloalkyl and —(C0-6alkyl)-CO2R6;
• R6 is independently selected from C1-6alkyl and NR5C(N)NH2, or two R6 join to form a ring selected from pyrrolidinyl, piperidinyl and azepanyl;
• X is CH2, N, O or S;
• W is selected from a single bond, —O—, —S—, —SO—, —SO2—, —CO—, —CO2—, —CONR6— and —NR6—;
• and
• n is 0-6;
• or a pharmaceutically acceptable salt or an individual diastereomer thereof.